Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Financing channel feed
Michael Pellini has just joined Bill Maris at Section 32 — focused on patient care and drug development
8 years ago
People
Atox Bio closes $30M round as it speeds through late-stage trials
8 years ago
Anti-aging startup ResTORbio gets $40M to fuel Phase IIb study
8 years ago
Looking to cure Type 1 diabetes, investors front $114M to launch a pioneering human study at Semma
8 years ago
People
Startups
New backers Sofinnova and Scopia bring Y-mAb's round to $80M for anti-cancer drugs
8 years ago
Frazier backs MavuPharma’s $20M round, brings in heavyweight execs to lead
8 years ago
Startups
Doug Williams ups the ante at Codiak Bio to $168.5M in a drive to first human study
8 years ago
People
Startups
RA backs Medeor’s $57M round as researchers fast forward to PhIII
8 years ago
AstraZeneca teams with China-owned fund to launch a new biopharma drug development company
8 years ago
China
Six top biotech VCs take a look at the latest trends, and offer their thoughts on 2018
8 years ago
People
French upstart Step Pharma raises €8.6M, taking immunosuppressive drugs to the clinic
8 years ago
ScPharmaceuticals raises $90M in IPO with heart failure drug on deck
8 years ago
What's a successful failure? Atlas' Booth sounds taps for Merck-backed Quartet Medicine
8 years ago
Startups
Arsanis prices $40M IPO for infectious disease work
8 years ago
X4 raises $27M to take Sanofi’s old drug through pivotal trial
8 years ago
Johns Hopkins has $65M to spend on taking their drugs right up to human studies
8 years ago
$49M round; experienced team; A-list VCs — Inozyme launches with rare disease strategy and a yen for bigger things to come
8 years ago
Startups
Award-winning sepsis project gets $13M and a shot at reopening an R&D avenue as FDA pitches out old gold standard
8 years ago
People
R&D
San Diego’s stealthy Odonate surfaces with $173M IPO
8 years ago
ImmusanT scores a $40M round for PhII celiac study, with biotech vet Tom Daniel joining the board
8 years ago
People
Torque takes tumor tech out of stealth with $25M backing, new CEO
8 years ago
Startups
Neurodegeneration upstart Denali outlines $100M IPO for its growing clinical work
8 years ago
Google backs I/O startup Arcus in $107M deal
8 years ago
Startups
Bill Gates has a $100M and a 5-point strategy to end 15 years of failure in Alzheimer’s R&D
8 years ago
R&D
First page
Previous page
133
134
135
136
137
138
139
Next page
Last page